Pyxis Oncology
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
321 Harrison Ave Fl 11 Ste 1, Boston, Ma...Phone Number
(617) 453-3596Website
www.pyxisoncology.comRevenue
$13.9 MillionStock Symbol
PYXSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Pyxis Oncology
Founded in 2019, Pyxis Oncology has assembled a differentiated portfolio of potent biologics, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies with the potential to further improve the outcome for patients with cancer. The company is headquartered in Cambridge, Massachusetts.Explore more
Pyxis Oncology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pyxis Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Pyxis Oncology had a recent Job posting/layoffs
Pyxis Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Pyxis Oncology has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Pyxis Oncology
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Pyxis Oncology recently announced quarterly report
Check out if Pyxis Oncology is spiking on competitors!
Funding: Get notified immidiatlly once Pyxis Oncology has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Pyxis Oncology launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Pyxis Oncology
Compare insights from companies similar to Pyxis Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Pyxis Oncology is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pyxis Oncology is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pyxis Oncology.
Pyxis Oncology financials insights
Gather financial insights about Pyxis Oncology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$22M
2021
Series B
$152M
Stock Offering
$168M
2026
Stock/Share Issuance
$114M
Pyxis Oncology Tech Stack
A closer look at the technologies used by Pyxis Oncology
Most Recent Scoops
Funding
Funding
Project
Pyxis Oncology has structured its MICVO dose expansion trial in head and neck cancer with two arms platinum plus PD-1 (current standard of care) and EGFR inhibitors plus PD-1 (emerging standard of care) with approximately 20 patients per arm, and expects the mid-year data set to include approximately 40 patients from dose expansion plus additional patients from the earlier study.
Medical Research, Clinical Operations
Project
reported a 71% response rate, a high disease control rate, and a clean safety profile from the combination study of MICVO with pembrolizumab in first-line head and neck cancer patients, with an H2 update planned to include data from both 3.6 mg and 4.4 mg doses across HPV positive and HPV negative patients.
Medical Research, Pharmaceuticals, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Pyxis Oncology News & Media
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose capPyxis Oncology Raises $50 Million in Private Placement; Warrants Could Add - TradingView
Pyxis Oncology announced a financing through a private placement of 19,600,153 common shares at $2.551 per share with accompanying common warrants, expected to yield approximately $50.0 million in gross proceeds at closing. The warrants, exercisable at $3.289 after MICVO Phase 1 data disclosure or…Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose capPyxis Oncology to Participate in Upcoming Investor Conferences
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences:
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pyxis Oncology
Sign Up For FreeTo access detailed company insights
Founded in 2019, Pyxis Oncology has assembled a differentiated portfolio of potent biologics, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies with the potential to further improve the outcome for patients with cancer. The company is headquartered in Cambridge, Massachusetts.... Read More
